Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Revenio Group Oyj Director's Dealing 2017

May 31, 2017

3236_rns_2017-05-31_b72aa34f-e01c-4e39-b9c8-4425ba0a422b.html

Director's Dealing

Open in viewer

Opens in your device viewer

Revenio Group Corporation: Managers' transactions

Revenio Group Corporation: Managers' transactions

Revenio Group Corporation, Managers' transactions, May 31, 2017 at 15:30

Revenio Group Corporation: Managers' transactions

Person subject to the notification requirement

Name: Kukkonen, Ari

Position: Other senior manager


Initial Notification

Reference number: 743700I27E0FWSXLKK04_20170524134242_2


Issuer

Name: Revenio Group Oyj

LEI: 743700I27E0FWSXLKK04


Transaction details

Transaction date: 2017-05-30

Nature of the Acceptance of a Stock Option
transaction:

Further details:

Linked to stock option programme

Instrument: Financial Instrument Linked to a Share or a Debt
Instrument

ISIN: FI4000261037

Volume: 5000

Unit price:

Aggregated transactions

Volume: 5000

Volume weighted average
price:

For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932

Distribution:
Nasdaq Helsinki
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit
for continuing operations standing at 30.1%. Revenio Group Corporation is listed
on Nasdaq Helsinki.

[]